Novo Nordisk tells Europe weight-loss drug will save money as well as lives
Novo Nordisk aims to persuade European governments to reimburse its obesity drug Wegovy for the most overweight individuals, according to CEO Lars Fruergaard Jorgensen, as the company seeks to expand in Europe by highlighting the medical and cost benefits of the treatment.